Literature DB >> 29559711

Rheumatoid arthritis: Moving towards IMPROVED drug-free remission.

Vivian P Bykerk1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29559711     DOI： 10.1038/nrrheum.2018.49

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  7 in total

Review 1.  Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.

Authors:  T Martijn Kuijper; Femke B G Lamers-Karnebeek; Johannes W G Jacobs; Johanna M W Hazes; Jolanda J Luime
Journal:  J Rheumatol       Date:  2015-10-01       Impact factor: 4.666

2.  A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.

Authors:  L Heimans; K V C Wevers-de Boer; K Visser; R J Goekoop; M van Oosterhout; J B Harbers; C Bijkerk; I Speyer; M P D M de Buck; P B J de Sonnaville; B A M Grillet; T W J Huizinga; C F Allaart
Journal:  Ann Rheum Dis       Date:  2013-05-28       Impact factor: 19.103

3.  Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.

Authors:  Gülşah Akdemir; Lotte Heimans; Sytske Anne Bergstra; Robbert J Goekoop; Maikel van Oosterhout; Johannes H L M van Groenendael; André J Peeters; Gerda M Steup-Beekman; Leroy R Lard; Peter B J de Sonnaville; Bernard A M Grillet; Tom W J Huizinga; Cornelia F Allaart
Journal:  Ann Rheum Dis       Date:  2017-09-28       Impact factor: 19.103

4.  Sustained remission with etanercept tapering in early rheumatoid arthritis.

Authors:  Paul Emery; Mohammed Hammoudeh; Oliver FitzGerald; Bernard Combe; Emilio Martin-Mola; Maya H Buch; Marek Krogulec; Theresa Williams; Stefanie Gaylord; Ronald Pedersen; Jack Bukowski; Bonnie Vlahos
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

5.  Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.

Authors:  Paul Emery; Gerd R Burmester; Vivian P Bykerk; Bernard G Combe; Daniel E Furst; Emilie Barré; Chetan S Karyekar; Dennis A Wong; Tom W J Huizinga
Journal:  Ann Rheum Dis       Date:  2014-11-03       Impact factor: 19.103

6.  Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study.

Authors:  Gülşah Akdemir; Marije K Verheul; Lotte Heimans; Kirsten V C Wevers-de Boer; Yvonne P M Goekoop-Ruiterman; Maikel van Oosterhout; Joop B Harbers; Casper Bijkerk; Gerda M Steup-Beekman; Leroy R Lard; Tom W J Huizinga; Leendert A Trouw; Cornelia F Allaart
Journal:  RMD Open       Date:  2016-02-15

7.  Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).

Authors:  Lotte Heimans; Gülşah Akdemir; Kirsten V C Wevers-de Boer; Yvonne P Goekoop-Ruiterman; Esmeralda T Molenaar; Johannes H L M van Groenendael; Andreas J Peeters; Gerda M Steup-Beekman; Leroy R Lard; Peter B J de Sonnaville; Bernard A M Grillet; Tom W J Huizinga; Cornelia F Allaart
Journal:  Arthritis Res Ther       Date:  2016-01-21       Impact factor: 5.156
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.